Recombinant Human Parathyroid Hormone

Assessment Status Rapid Review Complete
Drug Recombinant Human Parathyroid Hormone
Brand Natpar®
Indication Is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
Assessment Process
Rapid review commissioned 05/03/2018
Rapid review completed 21/05/2018
Rapid review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Natpar compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.